![Vivienne Green](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Vivienne Green
Corporate Officer/Principal at Australian Psychological Society
Vivienne Green active positions
Companies | Position | Start | End |
---|---|---|---|
Australian Psychological Society | Corporate Officer/Principal | - | - |
Career history of Vivienne Green
Former positions of Vivienne Green
Companies | Position | Start | End |
---|---|---|---|
Aviragen Therapeutics, Inc.
![]() Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Human Resources Officer | - | - |
BIOTA HOLDINGS LTD. | Human Resources Officer | 2011-06-30 | - |
Statistics
International
Australia | 3 |
United States | 2 |
Operational
Human Resources Officer | 2 |
Corporate Officer/Principal | 1 |
Sectoral
Health Technology | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 3 |
---|---|
Biota Holdings Pty Ltd.
![]() Biota Holdings Pty Ltd. Pharmaceuticals: MajorHealth Technology Biota Holdings Pty Ltd. operates as an anti infective drug development firm. The company was founded on October 2, 1985 and is headquartered in Notting Hil, Australia. | Health Technology |
Australian Psychological Society | |
Aviragen Therapeutics, Inc.
![]() Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Health Technology |
- Stock Market
- Insiders
- Vivienne Green
- Experience